Page 104 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 8. Monitoring criteria in protocols of observational management strategies with palliative intent in chronological order of starting
enrollment year (continued)
Center, Monitoring PSA Gleason # biopsy cores Imaging Behavioral Additional Triggers for interventions
Country schedule score /% cores indication laboratory
[Pubmed ID] tests
Enrollment
years
Taichung Every 3-6 mo √ – – – – – No treatment until there was
Veterans PSA and DRE (after evidence of cancer
hospital, (after 1990, 1990) progression.
Taiwan 143 introduction of
[12854876] PSA)

1983-1996
SPCG-4, Every 6 mo in the √ – Rebiopsy was A bone scan – Hemoglobin, Adjuvant local or systemic
Finland, first 2 yr, then not routinely and chest creatinine, treatment was not given.
Sweden, and every 1 yr undertaken 152 radiograph were alkaline TURP was as a treatment for
a
Iceland 144 obtained phosphatase local progression.
[12226148] annually until
1997; thereafter,
1989-1999 chest
radiographs
were obtained
annually for the
first 2 yr
b
Erasmus Univ. Usually Followed √ – – “Bone scan and – Alkaline Local and metastatic
hospital, clinically every 6 chest x-ray were phosphatase progression were evaluated.
Netherlands 145 mo; Follow-up repeated Subjective progression, like
[7544841] regimens varied regularly” obstructive micturition or pain,
among local was considered for treatment
≤1990; 1993- practices 150 decisions. 145
2006 150 The authors reported that of
13 patients with progression,
6 started treatment (5 for
subjective symptoms; 1 for
objective progression only).
The authors also reported that
PSA progression may serve
as a trigger point to
treatment. 150

54